FDA Issues Second CRL to Hengrui's Camrelizumab Combo Due to Manufacturing Issues
CompanyDrug

FDA Issues Second CRL to Hengrui’s Camrelizumab Combo Due to Manufacturing Issues

AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
CompanyLegal / IP

AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development

Shanghai Junshi Biosciences' Loqtorzi Approved for Hepatocellular Carcinoma Treatment
CompanyDrug

Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment

Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations
CompanyLegal / IP

Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations

HutchMed's Tazverik Receives Conditional Approval from China's NMPA for Lymphoma Treatment
CompanyDrug

HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment

Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
CompanyDeals

Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing

Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
CompanyDeals

Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases

Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct
CompanyLegal / IP

Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct

AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships
CompanyDeals

AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships

Innovent Biologics Doses First Patient with IBI354 in HeriCare-Ovarian01 Study
CompanyDrug

Innovent Biologics Doses First Patient with IBI354 in HeriCare-Ovarian01 Study

Everest Medicines' EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
CompanyDrug

Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application

Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
CompanyDeals

Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development